Monoclonal antibodies article comments
- Condition
- Long COVID
- At worst
- Severe (mostly bedbound)
- Ill for
- 4.5 years
- Published
- Dec 2025
Summary
Credits monoclonal antibody. An unnamed patient was ill 4.5y with severe long COVID, improved, then relapsed. Pemgarda gives 8-10 week remission per dose.
This summary was assembled from the coded record rather than written from a full reading of the page, so it is short. The original has the detail.
What they credit
Credits Biologics & antibodies, Monoclonal antibodies (casirivimab, Pemgarda).
Similar stories
-
Monoclonal antibodies article comments (Chris)
Chris is participating in a Vanderbilt clinical trial of baricitinib for long COVID, having started the drug on October 18, 2025. He reported feeling "the best I have since I got Covid," becoming functional though still limited. As of his comment he was…
-
Three Long-term Long COVID Patients, Three Rapid Recoveries
Pemivibart (Pemgarda), a monoclonal antibody infusion whose effect the article says typically lasts about a couple of months, was given to three long-term long COVID patients. A 70-year-old woman, sick for nearly a year, had her brain fog, breathlessness and…
-
No easy home runs: early Long COVID Paxlovid and monoclonal trials
Amy Engebretson took part in Yale's PaxLC trial of Paxlovid and has continued taking ritonavir, one of Paxlovid's components, because she says it "improved my symptoms quite a bit"; the article gives no specific dose or treatment duration for her. It does…
-
Three Severely Ill Long COVID Patients - Three Rapid Recoveries (patient 3)
The third patient, who had type II diabetes and was overweight, was severely ill with long COVID for about five months. After receiving the casirivimab and imdevimab cocktail the post reports his symptoms disappeared within a week. He was reportedly…